<DOC>
	<DOC>NCT01394952</DOC>
	<brief_summary>The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.</brief_summary>
	<brief_title>Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Type 2 diabetes with Hemoglobin A1c equal to or less than 9.5% (equal to or less than 81 mmol/mol) Antihyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or without a glucagonlike peptide1analog or basal insulin, or basal insulin alone On stable antihyperglycemic regimen for at least 3 months Age equal to or greater than 50 years with established clinical vascular disease, or age equal to or greater than 55 years and subclinical vascular disease or age equal to or greater than 60 years and at least 2 or more cardiovascular risk factors Uncontrolled diabetes requiring immediate therapy History of severe hypoglycemia in past year Acute coronary or cerebrovascular event within past 2 months Planned or anticipated revascularization procedure History of pancreatitis, hepatic insufficiency , chronic renal failure or of Ccell thyroid disorder Pregnancy or planned pregnancy during the trial period Completed or withdrawn from any study investigating dulaglutide</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Dulaglutide</keyword>
</DOC>